We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Alemtuzumab-Based Reduced-Intensity Conditioning Allogeneic Transplantation for Myeloma and Plasma Cell Leukemia - A Single- Institution Experience.
- Authors
Ramasamy, Karthik; Mahmood, Shameem; Lim, ZiYi; Corderoy, Sophie; Devereux, Stephen; Mufti, Ghulam J.; Pagliuca, Antonio; Schey, Stephen
- Abstract
Background: Reduced-intensity conditioning allogeneic transplantation for myeloma is associated with lower nonrelapse mortality and higher relapse rates in comparison with myeloablative conditioning transplants. Patients and Methods: We have retrospectively audited 19 patients with myeloma or primary plasma cell leukemia who received allogeneic transplantation with a uniform alemtuzumab-based reduced-intensity conditioning protocol. These patients had not been treated with bortezomib or lenalidomide before transplantation. Results: The treatment-related mortality at 1 year was (4/19) 21% with low incidence of graft-versus-host disease (6%) and 2-year progression-free survival and overall survival rates of 35% and 42%, respectively. Conclusion: Progression-free survival in this cohort of patients is comparable to previously published data of reduced-intensity conditioning allogeneic transplantation in myeloma. However, there is no plateau observed on the survival curves with a significant transplant-related mortality of 21%. Therefore, alemtuzumab-based allogeneic transplantation cannot be recommended as standard practice outside of clinical trials for treatment of myeloma.
- Publication
Clinical Lymphoma, Myeloma & Leukemia, 2011, Vol 11, Issue 2, p242
- ISSN
2152-2650
- Publication type
Article
- DOI
10.1016/j.clml.2011.03.004